MA53550A - Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci - Google Patents

Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci

Info

Publication number
MA53550A
MA53550A MA053550A MA53550A MA53550A MA 53550 A MA53550 A MA 53550A MA 053550 A MA053550 A MA 053550A MA 53550 A MA53550 A MA 53550A MA 53550 A MA53550 A MA 53550A
Authority
MA
Morocco
Prior art keywords
tubulysins
intermediates
preparation
alternative methods
alternative
Prior art date
Application number
MA053550A
Other languages
English (en)
French (fr)
Inventor
Wendel Doubleday
Qingwu Jin
Kun-Liang Wu
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MA53550A publication Critical patent/MA53550A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA053550A 2018-09-07 2019-09-06 Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci MA53550A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07

Publications (1)

Publication Number Publication Date
MA53550A true MA53550A (fr) 2021-12-15

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053550A MA53550A (fr) 2018-09-07 2019-09-06 Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci

Country Status (17)

Country Link
US (1) US20230002440A1 (enExample)
EP (1) EP3847161A1 (enExample)
JP (1) JP7511543B2 (enExample)
KR (1) KR20210073525A (enExample)
CN (1) CN112996778A (enExample)
AU (1) AU2019336231A1 (enExample)
BR (1) BR112021004317A2 (enExample)
CA (1) CA3111149A1 (enExample)
EA (1) EA202190699A1 (enExample)
IL (1) IL281090A (enExample)
MA (1) MA53550A (enExample)
MX (1) MX2021002570A (enExample)
SA (1) SA521421375B1 (enExample)
SG (1) SG11202102126VA (enExample)
TW (1) TWI825169B (enExample)
UA (1) UA128730C2 (enExample)
WO (1) WO2020051503A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020482800B2 (en) * 2020-12-23 2025-08-21 Genequantum Healthcare (Suzhou) Co., Ltd. Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2148886B1 (en) * 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
MA50124A (fr) * 2017-09-08 2020-07-15 Seattle Genetics Inc Procédé de préparation de tubulysines et d'intermédiaires de celles-ci

Also Published As

Publication number Publication date
SA521421375B1 (ar) 2024-02-11
EP3847161A1 (en) 2021-07-14
EA202190699A1 (ru) 2021-06-08
CN112996778A (zh) 2021-06-18
JP7511543B2 (ja) 2024-07-05
TWI825169B (zh) 2023-12-11
WO2020051503A1 (en) 2020-03-12
KR20210073525A (ko) 2021-06-18
CA3111149A1 (en) 2020-03-12
US20230002440A1 (en) 2023-01-05
AU2019336231A1 (en) 2021-03-18
TW202024043A (zh) 2020-07-01
BR112021004317A2 (pt) 2021-05-25
JP2021536475A (ja) 2021-12-27
SG11202102126VA (en) 2021-04-29
IL281090A (en) 2021-04-29
UA128730C2 (uk) 2024-10-09
MX2021002570A (es) 2021-06-08

Similar Documents

Publication Publication Date Title
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3893655A4 (en) METHOD OF PREPARING A PLANT PROTEIN COMPOSITION
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
EP3774709A4 (en) METHOD FOR REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM USING INHIBITORS OF HIF-2-ALPHA
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
EP3402483A4 (en) METHOD AND COMPOSITIONS FOR ACTIVATING GAMMA DELTA T CELLS
EP3328429A4 (en) PEPTIDES AND ANTIBODIES FOR THE DISPOSAL OF BIOFILMS
EP3891272A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3897717A4 (en) METHODS FOR THE PRODUCTION OF HETERODIMERS ANTIBODIES
EP3833340A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA
EP3768281A4 (en) COMPOSITIONS AND METHODS OF ACTIVATING T-CELLS AND CYTOKINES
EP3450426A4 (en) PROCESS FOR SYNTHESIS OF SILODOSINE AND INTERMEDIATE PRODUCT THEREOF
EP3361864A4 (en) DEVICES AND METHOD FOR PRODUCING A BIOLOGICAL SAMPLE FOR A CRYOPROCEDURE
EP3648773A4 (en) COMPOUNDS AND METHODS OF TRANSMEMBRANE DELIVERY OF MOLECULES
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
EP3902792A4 (en) PROCESS FOR THE PREPARATION OF ANTHRANILAMIDES
EP3867642A4 (en) PROCEDURE FOR SCREENING OF UBIQUITIN LIGASE AGONISTS
IL288090A (en) Expression of antigen-binding proteins in the nervous system
MA71753A (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
EP3801485A4 (en) PROTEIN AND PEPTIDE PURIFICATION PROCEDURES
EP3679050A4 (en) METHODS AND COMPOSITIONS FOR IMPROVED EXPRESSION OF RECOMBINANT PROTEINS